Annabel Spek

About

Annabel Spek is a clinical researcher specializing in urological oncology and stereotactic radiotherapy, with a particular focus on the application of robotic radiosurgery as a minimally invasive treatment alternative for urological cancers. Her work centers on stereotactic ablative body radiotherapy (SABR) and robotic radiosurgery systems such as CyberKnife, exploring their efficacy in treating renal cell carcinoma and recurrent prostate cancer in patients who are poor surgical candidates. Spek's most influential contribution — a propensity score-matched analysis comparing single-fraction robotic radiosurgery to open partial nephrectomy in renal cell carcinoma — has garnered 8 citations and demonstrated comparable oncological and functional outcomes between the two approaches, providing meaningful evidence supporting radiosurgery as a viable surgical alternative. Her earlier work on locally recurrent prostate cancer following radical prostatectomy further established single-fraction SABR as an effective and efficient treatment modality, while her foundational 2016 study laid groundwork for using robotic radiosurgery to spare kidney function in RCC patients. Collectively, Spek's research advocates for precision, non-invasive treatment strategies that expand options for vulnerable patient populations, contributing to an evolving paradigm in urological cancer management.

Research Focus

Key Achievements

Top Papers

1. 1
   Propensity Score-Matched Analysis of Single Fraction Robotic Radiosurgery Versus Open Partial Nephrectomy in Renal Cell Carcinoma: Oncological Outcomes

   8 citations · 2022
2. 2
   Single‐fraction image‐guided robotic radiosurgery efficiently controls local prostate cancer recurrence after radical prostatectomy

   3 citations · 2020
3. 3
   Single-fraction radiosurgery for the treatment of renal cell carcinoma.

   2 citations · 2016

Key Collaborators

Contact & Links